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ABSTRACT
The purpose of this research was to perform a granulometri-
cal and flow properties study of a morphine polymeric com-
plex and determine the influence of 3 variables—particle
size of complex, pH value, and ionic strength of the dissolu-
tion medium—on the dissolution behavior. The morphine-
Eudragit L complex was produced in aqueous medium from
morphine hydrochloride saturated solution and Eudragit L
30D diluted until 12% wt/vol and partially neutralized
(40%). To determine the rheological behavior of the com-
plex, several rheological tests were developed: bulk and
tapped densities, Hausner ratio, angle of repose, and flow
rate. The results corresponding to the technological study
suggest that the 100- to 250-µm fraction can be considered
as free flowing powder. In relation to the dissolution behav-
ior of the complex, the results indicate that the ionic strength
has been detected as the most influencing factor when val-
ues below physiological conditions are used. In conclusion,
no technological problems for the production of further
solid dosage forms are expected. Furthermore, no changes
in the dissolution profiles of the complex have been detect-
ed when ionic strength values are inside the physiological
range.
KEYWORDS: morphine-Eudragit complex, rheology, disso-
lution medium, dissolution medium, pH.
INTRODUCTION
Morphine given regularly by mouth is recommended
throughout the world for the management of severe pain in
cancer patients when less-effective drugs are no longer ade-
quate. Moreover, controlled release oral morphine systems
offer the clinical advantage of less frequent dosing, with an
increase in quality of life for patients with chronic pain
requiring repeated-dose opioid analgesia.1
Eudragit L 30D was used as a carrier to prepare morphine
polymeric complexes in order to obtain controlled release
systems by a reaction between the drug and the polymer,
yielding a chemical drug-polymer interaction. The complex-
ation technique used has been patented by University of
Seville.2 In this technique, the acrylic resin is partially dilut-
ed and neutralized. The polymer in its sodium salt form
reacts with the added drug to obtain a precipitate—the mor-
phine complex. Several preliminary studies were realized
over this initial complex. A hydrogen bond interaction was
reported between morphine and Eudragit.3 The in vitro dis-
solution behavior was studied.4,5 The obtained results4,5
indicated that there should be another factor, as well as pH,
influencing the dissolution profiles. Finally, a preclinical
study was performed in rats. The results indicated that this
complex had a marked analgesic effect from 30 minutes to
8 hours.6
In further studies, several modifications on the initial prepa-
ration technique were performed in order to optimize the
elaboration process of complexes.7 So, critical factors affect-
ing the development of the proposed reaction were estab-
lished, and parameters such as morphine content (percentage
wt/wt of morphine-HCl in the complex), morphine entrap-
ment (percentage wt/wt of morphine-HCl incorporated into
the complex, with respect to the total amount of drug added
to the reaction medium), and weight efficiency (percentage
of the total weight of the substances employed [drug plus
excipients] that is transformed in complex) were evaluated.
These parameters have been described previously.7
Considering the experimental conditions assayed, the best
efficiency complexation was yielded by using Eudragit L
12D 40% neutralized and adding morphine necessary to
react with the 54% carboxylic acid/carboxylate groups of the
polymer (35% drug excess with respect to the stoichiometric
drug amount corresponding to the 40% neutralized groups).
So, this complex has been selected to continue further stud-
ies. Considering the previously reported results, in the pres-
ent work a more detailed study has been performed over this
selected complex.
The aim of the present study is as follows: (1) to carry out a
granulometrical and flow properties study of the previously
indicated complex, and (2) to determine the influence of 3
variables over the dissolution behavior: particle size of com-
plex, pH value, and ionic strength of the dissolution medium.
These 2 last factors are particularly important considering
that the complex is based on the interaction between Eudragit
and morphine by means of hydrogen bonds3 so it can be
potentially sensitive to pH and ionic strength variations.
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MATERIALS AND METHODS
Materials
The following materials were used: morphine hydrochloride
(Alcaliber, Madrid, Spain); Eudragit L 30D (Degussa,
Barcelona, Spain); sodium hydroxide (Acofarma, Tarrasa,
Spain); McIlvaine’s citric acid-phosphate (to obtain several
pH values: 2.2, 4.0, 6.0, and 8.0) (Panreac Química,
Barcelona, Spain); sodium chloride, methanol (high per-
formance liquid chromatography [HPLC] grade), and
diammonium hydrogen phosphate (Merck, Barcelona,
Spain).
Preparation of Morphine Complexes
The morphine-Eudragit L complex was elaborated in aque-
ous medium from morphine hydrochloride saturated solution
and Eudragit L 30D (30% wt/vol). According to previous
results,7 the polymer was diluted to 12% wt/vol and partially
neutralized (40%). The amount of morphine hydrochloride
added was calculated to react with the 54% carboxylic/car-
boxylate groups of the polymer (35% drug excess with
respect to the stoichiometric drug amount corresponding to
the 40% neutralized groups). The obtained white solid was
then separated by filtration and dried in an oven (model 204,
Selecta, Barcelona, Spain). After crushing (cutting method,
Moulinex, Madrid, Spain), the product was opportunely
sieved (model Vibro, Retsch, Haan, Germany).
Particle Size Distribution
In order to determine the size particle distribution of the com-
plex and to select the optimum crushing time, a granulomet-
rical study was developed after several times of pulverization
(40, 60, 120, and 180 seconds). A sieve method (Retsch) was
used to obtain different powder fractions.
To characterize the size particle distribution of different pow-
ders obtained, probit units were calculated as follows:
where X indicates size particle and µ, mean particle size.
Particle Properties and Bulk Flow
To determine the rheological behavior of the complex, sever-
al rheological tests were developed8:
• Bulk density (ρ0): 25 g of powder complex was
poured into a glass measuring cylinder (SBS-model
Vol-1), measuring the initial volume occupied (V0).
• Tapped density (ρ1250): the same cylinder with the
powder was then automatically tapped 1250 times
(constant volume), measuring the final volume
occupied.
• Hausner ratio (HR) and percentage of compressibil-
ity (%C): used as dimensionless parameters; these
parameters were calculated according to the relation
between tapped and bulk densities. The equations
used were the following:
• Angle of repose (°): it has been used as indirect
method of quantifying powder flowability; this
measurement was performed using 10 g of the pow-
der in study and a funnel described in Real
Farmacopea Española.8
• Flow rate (g/s): the simplest method of determining
powder flowability directly is to measure the rate at
which the powder discharges from a funnel; 50 g of
the powder in study was added to the funnel
described above. The time period for the material to
flow through this funnel was determined. Dividing
the discharged powder mass by this time yields a
flow rate that can be used for quantitative compari-
son of different powders.
Quantification of the Morphine
An HPLC method was chosen for quantifying morphine:
Hitachi HPLC system manager (Frankfurt, Germany), pump
L-7100, manual injector 77251, diode array detector L-7455,
interphase D-7000, column Merck Aluspher 100 RP-select
B, 5 µm particle size, 12.5 cm × 4 mm inner diameter (ID).
A flow rate of 1 mL/min was employed, and the variable
wavelength detector was set at 273 nm. The selected mobile
phase was methanol/purified water/diammonium phosphate
50:50:0.01 vol/vol/wt. The validation of the chromatograph-
ic method, in terms of linearity, precision, and accuracy was
described in a previous study.7
In Vitro Dissolution Study
The in vitro dissolution study was performed at 37°C ± 0.5°C
in the United States Pharmacopeia (USP) 26 basket appara-
tus (model D-6, Turu Grau, Tarrasa, Spain) at a speed of 50
rpm over 4 hours. Samples of 200 mg of morphine polymer-
ic complex, placed by hand in colorless lock-cap gelatin cap-
sules, were assayed in triplicate, using 700 mL of dissolution
medium. At predetermined time intervals, samples were
assayed by HPLC.
% C = ρ1250 - ρ0ρ1250
× 100 (3)
HR = ρ1250ρ0
(2)
Probit = X - µSD + 5 (1)
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To characterize the dissolution behavior of the complex, the
influence of 3 variables over the dissolution characteristics
(particle size of complexes, pH value, and ionic strength of
the dissolution medium) was determined.
Statistical Analyses
Statistical analyses were performed on area under the curve
(AUC) values obtained from different dissolution profiles.
The differences between groups were analyzed using a
Student-Newman-Keuls test following significant main
effects of treatment by analysis of variance (ANOVA).
Statistical significance was accepted at the 5% level (P < .05).
RESULTS AND DISCUSSION
Size Particle Distribution
Tables 1, 2, 3, and 4 show data obtained in relation to size
particle distribution for each crushing time. A logarithmic
normal distribution was found. The good fitting obtained
indicates that this model provides an adequate characteriza-
tion of the size particle distribution of the complex.
On the other hand, Figure 1 shows the size particle distribu-
tion as a function of several crushing times. As can be
observed, the quantitative data corresponding to the mean
particle size for each crushing time are as follows:
• 40 seconds: µ = 54.90 µm (SD = 71.05 µm)
• 60 seconds: µ = 46.54 µm (SD = 70.90 µm)
• 120 seconds: µ = 30.68 µm (SD = 36.15 µm)
• 180 seconds: µ = 28.30 µm (SD = 24.03 µm)
Powder particle size is a critical factor to take into account
when solid dosage forms are elaborated. In this case, the con-
trol of this parameter is crucial as the obtained morphine
complex will be processed to obtain oral controlled release
forms. So, the particle sizes of the powder product may be
defined during preformulation studies to avoid problems dur-
ing production.
Figure 1 shows that after either 40 or 60 seconds of crushing
time, the obtained particulate size distribution is similar,
being 50 to 150 µm the majority fraction. Over 120 seconds
of crushing, the <50 µm fraction increases significantly. This
important decrement in the particle size can produce impor-
tant effects over the technological and biopharmaceutical
properties of the product.
Table 1. Particle Size Characterization of the Complex
After 40 Seconds Crushing*
Size Particle
(µm) % wt/wt
%
Accumulated Probit
< 50 16.6 16.6 4.006
50 - 150 57.9 74.5 5.643
150 - 250 21.8 96.3 6.751
250 - 350 2.6 98.9 7.326
350 - 450 0.8 99.7
> 450 0.3 100
*µ = 55.12 µm; SD = 61.35 µm; r2 = 0.9950.
Table 2. Particle Size Characterization of the Complex
After 1 Minute of Crushing*
Size Particle
(µm) % wt/wt
%
Accumulated Probit
< 50 41.6 41.6 4.798
50 - 150 56.2 97.8 7.054
150 - 250 1.7 99.5 7.326
250 - 350 0.3 99.7
350 - 450 0.2 99.9
> 450 0.1 100
*µ = 45.99 µm; SD = 69.35 µm; r2 = 0.9886.
Table 3. Particle Size Characterization of the Complex
after 2 minutes of Crushing*
Size Particle
(µm) % wt/wt
%
Accumulated Probit
< 50 23.2 23.2 4.261
50 - 150 60.1 83.3 5.954
150 - 250 12.3 95.6 6.751
250 - 350 1.9 97.5 6.881
350 - 450 1.3 98.2 7.326
> 450 1.2 100
*µ = 30.68 µm; SD = 36.15 µm; r2 = 0.9934.
Table 4. Particle Size Characterization of the Complex
after 3 Minutes of Crushing*
Size Particle
(µm) % wt/wt
%
Accumulated Probit
< 50 38.2 38.2 4.695
50 - 150 57.0 95.3 6.645
150 - 250 3.9 99.2 7.326
250 - 350 0.5 99.6
350 - 450 0.2 99.8
> 450 0.2 100
*µ = 26.61 µm; SD = 31.70 µm; r2 = 0.9456.
Figure 1. Particle size distribution after several crushing
times.
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For further studies, 2 granulometrical fractions (<100 µm
and 100-250 µm) will be used to produce tablets based on
morphine complex, in order to study the influence of mean
particle size of the complex over the biopharmaceutical
behavior of the tablets.9 Figure 2 shows the percentage
(wt/wt) of these fractions in the complex powder as a func-
tion of crushing time. On the basis of the obtained results, 40
seconds of crushing time was selected because this time pro-
vides the highest proportions of these 2 granulometrical frac-
tions. Moreover, this short time allows for (1) reducing the
energy consumption during the milling process, and (2)
decreasing the exposure of the complex solid to damage sit-
uations during the operation (eg, heat, vibration).
Particle Properties and Bulk Flow
The rheological study was performed using the complex
powder obtained after 40 seconds of crushing time. The fol-
lowing granulometrical fractions were used: 0 to 250, 0 to
100, and 100 to 250 µm. Table 5 shows bulk and tapped den-
sities data obtained for each granulometrical fraction. The
higher differences observed between values of both densities
are found in the <100 µm and <250 µm fractions, indicating
the presence of bigger interparticular spaces in comparison
with the 100 to 250 µm fraction.
HR and %C, angle of repose, and flow rate data obtained are
shown in Table 6. According to HR and %C, the better flowa-
bility corresponds to 100 to 250 µm fraction. Its %C < 18%
(Carr’s index) indicates good flow (free flowing powders)
and its HR ≈ 1.2 shows that this powder has low interpartic-
ular frictions.
According to these results, it can be concluded that both
granulometrical fractions (<100 µm and 100-250 µm) exhib-
it adequate rheological properties.
As a function of these results, it can be concluded that for fur-
ther studies, no rheological problems in the elaboration of the
morphine oral delivery systems are expected.
Dissolution Study of the Complex
Influence of the Particle Size of the Complex Over the
Dissolution Behavior
Purified water as dissolution medium was used. The dissolu-
tion profiles obtained as a function of particle size of complex-
es are showed in Figure 3. In order to compare and to evaluate
these dissolution data, a mathematical model independent of
the dissolution process was used.10 This model establishes 2
comparison factors: the difference factor (ƒ1) and the similari-
ty factor (ƒ2). These factors are easily calculated and provide a
simple measure of similarity between pairs of dissolution pro-
files but do not provide information on individual batches.
The difference factor (ƒ1) is the percentage difference
between 2 dissolution profiles at each time interval:
where Rt indicates the released amount of drug of reference
formulation; and Tt, the released amount of drug of test
formulation.
ƒ1 = [Σ (( | Rt - Tt | ) / Σ Rt )] × 100 (4)
Figure 2. Particle size distribution after several crushing
times.
Table 5. Bulk and Tapped Densities (g/mL) for Each Granulometrical Fraction Indicated*
Size Particle ρ0 (g/mL) SD CV (%) ρ1250 (g/mL) SD CV (%)
< 250 µm 0.630 0.003 0.725 0.842 0.005 0.968
100 - 250 µm 0.614 0.007 1.170 0.744 0.009 1.220
< 100 µm 0.583 0.006 1.096 0.782 0.006 0.769
*CV indicates the coefficient of variation.
Table 6. Hausner Ratio, Percentage of Compressibility, Angle of Repose, and Flow Rate (g/s) Corresponding to the Particle
Sizes Indicated*
< 250 µm 100 - 250 µm < 100 µm
%C HR ° g/s %C HR ° g/s %C HR ° g/s
Mean 25.17 1.34 21.46 17.61 17.41 1.21 22.17 34.02 25.46 1.34 22.84 14.38
SD 1.12 0.02 4.096 4.44 0.95 0.01 1.26 2.42 0.83 0.02 3.35 0.22
CV (%) 4.46 1.50 19.09 25.18 5.47 1.14 5.70 7.12 3.24 1.12 14.64 4.96
%C indicates percentage of compressibility; HR, Hausner ratio; (°), angle of repose; and CV indicates coefficient of variation.
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If the dissolution profiles are superimposed, ƒ1 reaches a
value of 0, whereas the factor value increases when the dif-
ferences between dissolution profiles also increase.
The similarity factor can be calculated using the following
expression:
where n indicates the number of experimental data.
From a practical point of view, values of ƒ1 between 0 and 15
and ƒ2 between 50 and 100 can be considered as superim-
posed dissolution profiles.
Table 7 shows the obtained results corresponding to the com-
parison between the fractions (<250 µm, <100 µm, and <250
µm, 100-250 µm). It can be observed that there are not any
differences among the obtained dissolution profiles. So, the
dissolution curves can be considered as superimposed. In this
sense, the factor “particle size” can be obviated for the fol-
lowing sections.
Influence of the Ionic Strength of the Dissolution Medium
This study was performed with the fraction <250 µm of the
complex. A McIlvaine’s citric acid-phosphate buffer solution
was used as dissolution medium to fit a pH value of 5.0, so
as to obviate any possible interference due to the dissolution
of polymer (soluble above pH 5.5). Appropriate dilutions or
several amounts of NaCl were added in order to obtain dif-
ferent values of ionic strength: 0.001, 0.005, 0.01, 0.05, and
0.2 M. NaCl was used because sodium is reported as the
most common ion in the upper gastrointestinal tract (GIT).11
In a previous study,5 several in vitro dissolution studies of
morphine complex at pH constant values were developed.
In that study, the dissolution rate of the complex at pH 1.2
was surprisingly high considering the pH-dependent solu-
bility of Eudragit L. These results would indicate the pres-
ence of another factor, different from pH, influencing the
dissolution behavior of the complex. Taking into account
that the interaction between morphine and Eudragit is by
means of hydrogen bonds,3 the ionic strength of the disso-
lution medium should be considered as an important influ-
encing factor on the dissolution behavior of the morphine
complex.
The experimental data were fitted to Korsmeyer Equation12:
where Qt/Q∞ is the drug-released ratio at different times; KK,
is the Korsmeyer constant; and n, is a parameter that defines
the release mechanism.
Figure 4 shows the dissolution profiles obtained as a function
of ionic strength of dissolution medium. Table 8 shows the
kinetic study data of the same curves. In all cases, a signifi-
cant and positive effect of ionic strength can be observed. As
a function of KK values obtained, the higher the medium
ionic strength is, the higher the drug dissolution rate is. It is
Qt / Q∞ = KK · tn (6)
ƒ2 = 50 × log {[1 / (1 + (Σ (Rt - Tt)2 ) / n)]½ × 100} (5)
Figure 3. Release profiles of morphine complex as a func-
tion of particle size.
Table 7. Comparative Study of ƒ1 and ƒ2 Values
Corresponding to the Particle Sizes Indicated*
Particle Size Fractions ƒ1 ƒ2
<250 µm / <100 µm 11.00 73.61
<250 µm / 100-250 µm 8.28 76.15
*The difference factor is ƒ1 and the similarity factor is ƒ2.
Figure 4. Release profiles of morphine complex as a func-
tion of ionic strength.
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concluded that the factor “ionic strength” exerts a great influ-
ence over the dissolution behavior of the complex.
As shown in Figure 4, ionic strength values greater than 0.01
resulted in no significant changes in drug release (P > .05).
This finding implies that there must be a critical value of
ionic strength over which this factor exerts no further effect
on morphine release from the complex. Nevertheless, from a
biopharmaceutical point of view, it can be concluded that
changes of ionic strength within physiological range of GIT
(ionic strength range, 0.11-0.14) will not affect the in vivo
performance of the morphine complex.13,14 Therefore, ionic
strength may not be considered as a contributing factor to
any indirect food effects, and the polymeric complex can be
basically regarded as a system independent of ionic strength
under normal physiological conditions.
The release exponent n at different levels of ionic strength
was almost unchanged, which clarified that the ionic strength
does not significantly modify the release mechanism of the
complex.
Influence of the pH Value of the Dissolution Medium
Several McIlvaine’s citric acid-phosphate buffer solutions
were used to obtain different pH values (2.2, 4.0, 6.0, and
8.0). In a first step of this study and to obviate the influence
of ionic strength, all the dissolution media were fitted to an
ionic strength value of 0.005. A fraction of <250 µm of the
complex was used for this study.
Figure 5 shows the dissolution profiles obtained as a function
of pH value, and Table 9 shows the kinetic study data of the
same curves. As a function of KK values, over pH > 4, the
higher the medium pH value is, the higher the drug dissolu-
tion rate is. Significant differences (P < .05) were obtained.
The post hoc analysis indicated that these profiles belong to
3 homogeneous subsets (pH values 6, 8, and 2.2-4). This sit-
uation is caused by the pH-dependent solubility of the poly-
mer (the solubility of Eudragit L 30D begins at pH > 5.5. So,
under these ionic strength conditions, below physiological
values, there is a clear influence of pH dissolution medium
over the release profiles of the complex.
Nevertheless, a complete release of morphine is not reached,
even with the highest pH value (pH = 8). This circumstance
can be due to the fact that, although Eudragit is a pH-depend-
ent polymer, the concentration of ions (0.005) is far away from
the physiological range.13 It can be deduced that there must be
a minimum ionic strength value to achieve a complete release
of morphine from this polymeric complex. Therefore, and tak-
ing into account the nature of drug-polymer interaction (based
on hydrogen bonds), it should be concluded that the impact of
ionic strength on the release behavior of the complex is more
important than the pH of the dissolution medium.
In order to realize the study under physiological conditions,
in a second step of this study, the same experiments were per-
formed using an ionic strength value of 0.1. Figure 6 and
Table 10 show the obtained kinetic study data. As can be
seen, a complete release of morphine is reached at the end of
the assay, even with the lowest pH value (pH = 2.2).
Significant differences (P < .05) were obtained. The post hoc
analysis indicated that these differences correspond to pH =
8. This circumstance is related to the fact that under physio-
logical ionic strength conditions, the influence of pH appears
only at values allowing a high dissolution rate of the poly-
mer. This circumstance indicates again the marked influence
of the ionic strength over the release process of this complex,
in comparison with the former study.
Under physiological conditions of ionic strength, there is a
direct relation between the pH value of the dissolution medi-
um and the release rate of the process.
Table 8. Kinetic Study Data Using the Korsmeyer
Equation as a Function of Ionic Strength*
Ionic Strength (M) n Kk r2
0.001 0.343 0.090 0.998
0.005 0.410 0.108 0.999
0.01 0.412 0.140 0.998
0.05 0.410 0.155 0.993
0.2 0.477 0.112 0.997
*pH = 5.0.
Figure 5. Release profiles of morphine complex as a func-
tion of pH (ionic strength value of 0.005).
Table 9. Kinetic Study Data Using the Korsmeyer
Equation as a Function of pH*
pH n Kk r2
2.2 0.4727 0.0575 0.9994
4.0 0.4678 0.0607 0.9993
6.0 0.4997 0.0695 0.9980
8.0 0.3890 0.1460 0.9998
*Ionic strength value of 0.005 M.
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CONCLUSION
Therefore, considering the experimental studied conditions,
the ionic strength has been identified as the most influencing
factor. Moreover, it can be concluded that (1) a complete
release of morphine from the complex is achieved under
physiological conditions of ionic strength, independent of the
pH values, and (2) considering physiological conditions,
changes of ionic strength do not imply any modifications of
the release profile of drug from the polymeric system.
In conclusion, 40 seconds has been determined to be suitable
crushing time in order to obtain 2 concrete granulometrical
fractions (<100 µm and 100-250 µm). The fraction 100-250
µm can be considered as free flowing powder. Thus, it can be
concluded that no technological problems in the elaboration
of further solid dosage forms are expected. In relation to the
study of the dissolution behavior of the complex, it has been
found that the factor “ionic strength” exerts a great influence
over the dissolution behavior of the complex when its values
are below physiological conditions.
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